Gilead Builds Up Trodelvy Data In TNBC Ahead Of Competition
Executive Summary
Phase III sub-analyses presented at ESMO show the drug providing a survival benefit in a complex subpopulation, as well as improvements to quality of life.
You may also be interested in...
Trodelvy’s Phase III Breast Cancer Results Raise More Questions Than Answers
Gilead is staying mum about the TROPiCS-02 data, which is fueling speculation that the drug’s benefit may have been modest.
Gilead Sees Room For Trodelvy In European Markets
Gilead looks set to expand its lead position in the triple-negative breast cancer (TNBC) market in Europe with a positive opinion for Trodelvy from the CHMP.
Gilead Teases Big Cancer Drug Readouts In Second Half
The company’s two approved cell therapies led growth in oncology. But despite oncology currently accounting for a small share of Gilead’s overall business, analysts expect big readouts later in the year.